Biogen receives approval of aducanumab in the UAE for the treatment of Alzheimer’s disease.

The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has announced publicly the approval of aducanumab (100 mg/mL solution for injection) for the treatment of Alzheimer’s disease.

The UAE is the second country in the world following the United States Food and Drug Administration’s (US FDA) accelerated approval on June 7, 2021, to approve this first-in-class treatment that addresses a defining pathology of Alzheimer’s disease by reducing amyloid beta plaques in the brain.

The treatment will be available in the UAE in the coming months.

For media information, contact:
Biogen Intercontinental Region
intercontinentalregion@biogen.com

Biogen-135296